Cue Biopharma Inc (CUE)

$1.5

-0.07

(-4.46%)▲

Market is closed - opens 7 PM, 24 Apr 2024

Insights on Cue Biopharma Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 2.1M → 1.82M (in $), with an average decrease of 13.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -11.00M → -13.43M (in $), with an average decrease of 22.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 45.1% return, outperforming this stock by 102.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 238.3% return, outperforming this stock by 325.4%

Performance

  • $1.50
    $1.60
    $1.50
    downward going graph

    0.0%

    Downside

    Day's Volatility :6.25%

    Upside

    6.25%

    downward going graph
  • $1.47
    $5.12
    $1.50
    downward going graph

    2.0%

    Downside

    52 Weeks Volatility :71.29%

    Upside

    70.7%

    downward going graph

Returns

PeriodCue Biopharma IncSector (Health Care)Index (Russel 2000)
3 Months
-44.72%
-0.4%
0.0%
6 Months
-8.72%
9.6%
0.0%
1 Year
-57.91%
3.9%
-1.3%
3 Years
-87.13%
12.8%
-22.1%

Highlights

Market Capitalization
75.9M
Book Value
$0.79
Earnings Per Share (EPS)
-1.11
Wall Street Target Price
9.4
Profit Margin
0.0%
Operating Margin TTM
-750.96%
Return On Assets TTM
-42.53%
Return On Equity TTM
-98.73%
Revenue TTM
5.5M
Revenue Per Share TTM
0.12
Quarterly Revenue Growth YOY
1106.0%
Gross Profit TTM
1.2M
EBITDA
-51.4M
Diluted Eps TTM
-1.11
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.03
EPS Estimate Next Year
-1.0
EPS Estimate Current Quarter
-0.28
EPS Estimate Next Quarter
-0.27

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Cue Biopharma Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 526.67%

Current $1.50
Target $9.40

Company Financials

FY18Y/Y Change
Revenue
1.1M
-
Net Income
-39.0M
↑ 67.77%
Net Profit Margin
-3.4K%
-
FY19Y/Y Change
Revenue
3.5M
↑ 202.64%
Net Income
-36.7M
↓ 5.86%
Net Profit Margin
-1.1K%
↑ 2350.28%
FY20Y/Y Change
Revenue
3.2M
↓ 8.78%
Net Income
-44.8M
↑ 22.04%
Net Profit Margin
-1.4K%
↓ 358.54%
FY21Y/Y Change
Revenue
14.9M
↑ 373.68%
Net Income
-44.2M
↓ 1.39%
Net Profit Margin
-295.56%
↑ 1124.23%
FY22Y/Y Change
Revenue
1.2M
↓ 91.67%
Net Income
-52.8M
↑ 19.55%
Net Profit Margin
-4.2K%
↓ 3944.31%
FY23Y/Y Change
Revenue
5.5M
↑ 340.88%
Net Income
-50.7M
↓ 3.91%
Net Profit Margin
-924.1%
↑ 3315.77%
Q3 FY22Q/Q Change
Revenue
68.0K
↑ 161.54%
Net Income
-10.9M
↓ 18.36%
Net Profit Margin
-16.0K%
↑ 35255.32%
Q4 FY22Q/Q Change
Revenue
151.2K
↑ 122.39%
Net Income
-14.5M
↑ 32.86%
Net Profit Margin
-9.6K%
↑ 6440.74%
Q1 FY23Q/Q Change
Revenue
187.0K
↑ 23.66%
Net Income
-13.2M
↓ 8.62%
Net Profit Margin
-7.1K%
↑ 2494.69%
Q2 FY23Q/Q Change
Revenue
1.4M
↑ 639.04%
Net Income
-13.2M
↓ 0.17%
Net Profit Margin
-954.05%
↑ 6109.05%
Q3 FY23Q/Q Change
Revenue
2.1M
↑ 51.95%
Net Income
-11.0M
↓ 16.53%
Net Profit Margin
-524.05%
↑ 430.0%
Q4 FY23Q/Q Change
Revenue
1.8M
↓ 13.29%
Net Income
-13.4M
↑ 22.07%
Net Profit Margin
-737.73%
↓ 213.68%
FY18Y/Y Change
Total Assets
45.4M
↓ 32.25%
Total Liabilities
11.4M
↑ 113.06%
FY19Y/Y Change
Total Assets
71.6M
↑ 57.85%
Total Liabilities
17.0M
↑ 49.42%
FY20Y/Y Change
Total Assets
99.5M
↑ 39.0%
Total Liabilities
20.6M
↑ 21.16%
FY21Y/Y Change
Total Assets
83.4M
↓ 16.21%
Total Liabilities
17.9M
↓ 13.16%
FY22Y/Y Change
Total Assets
91.3M
↑ 9.45%
Total Liabilities
25.6M
↑ 42.95%
FY23Y/Y Change
Total Assets
61.5M
↓ 32.59%
Total Liabilities
24.4M
↓ 4.51%
Q3 FY22Q/Q Change
Total Assets
76.3M
↓ 9.97%
Total Liabilities
25.5M
↑ 2.17%
Q4 FY22Q/Q Change
Total Assets
91.3M
↑ 19.64%
Total Liabilities
25.6M
↑ 0.25%
Q1 FY23Q/Q Change
Total Assets
81.7M
↓ 10.52%
Total Liabilities
26.7M
↑ 4.16%
Q2 FY23Q/Q Change
Total Assets
73.2M
↓ 10.43%
Total Liabilities
27.2M
↑ 1.85%
Q3 FY23Q/Q Change
Total Assets
68.9M
↓ 5.84%
Total Liabilities
26.2M
↓ 3.45%
Q4 FY23Q/Q Change
Total Assets
61.5M
↓ 10.68%
Total Liabilities
24.4M
↓ 6.78%
FY18Y/Y Change
Operating Cash Flow
-26.4M
↑ 116.63%
Investing Cash Flow
-20.4M
↑ 1589.18%
Financing Cash Flow
4.2M
↓ 93.26%
FY19Y/Y Change
Operating Cash Flow
-30.8M
↑ 16.61%
Investing Cash Flow
3.4M
↓ 116.93%
Financing Cash Flow
50.8M
↑ 1114.53%
FY20Y/Y Change
Operating Cash Flow
-32.5M
↑ 5.51%
Investing Cash Flow
4.5M
↑ 29.27%
Financing Cash Flow
58.6M
↑ 15.41%
FY21Y/Y Change
Operating Cash Flow
-38.8M
↑ 19.52%
Investing Cash Flow
9.1M
↑ 104.42%
Financing Cash Flow
19.2M
↓ 67.19%
FY22Y/Y Change
Operating Cash Flow
-41.8M
↑ 7.64%
Investing Cash Flow
-24.6M
↓ 370.19%
Financing Cash Flow
53.7M
↑ 178.99%
Q3 FY22Q/Q Change
Operating Cash Flow
-6.9M
↓ 46.52%
Investing Cash Flow
-29.5M
↑ 47512.9%
Financing Cash Flow
-9.0K
↓ 100.08%
Q4 FY22Q/Q Change
Operating Cash Flow
-10.5M
↑ 53.02%
Investing Cash Flow
5.0M
↓ 116.93%
Financing Cash Flow
27.4M
↓ 304579.26%
Q1 FY23Q/Q Change
Operating Cash Flow
-10.8M
↑ 3.03%
Investing Cash Flow
15.0M
↑ 200.09%
Financing Cash Flow
388.0K
↓ 98.58%
Q2 FY23Q/Q Change
Operating Cash Flow
-10.4M
↓ 4.26%
Investing Cash Flow
5.0M
↓ 66.67%
Financing Cash Flow
2.1M
↑ 441.49%

Technicals Summary

Sell

Neutral

Buy

Cue Biopharma Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cue Biopharma Inc
Cue Biopharma Inc
-15.59%
-8.72%
-57.91%
-87.13%
-81.35%
Moderna, Inc.
Moderna, Inc.
-5.36%
32.83%
-24.38%
-39.84%
322.91%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.34%
13.15%
12.94%
84.22%
161.57%
Novo Nordisk A/s
Novo Nordisk A/s
-2.94%
28.97%
46.95%
238.27%
414.84%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.87%
8.77%
20.15%
83.53%
128.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cue Biopharma Inc
Cue Biopharma Inc
NA
NA
NA
-1.03
-0.99
-0.43
NA
0.79
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.77
25.77
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.13
46.13
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.39
28.39
0.53
16.72
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cue Biopharma Inc
Cue Biopharma Inc
Buy
$75.9M
-81.35%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
322.91%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.4B
161.57%
25.77
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.3B
414.84%
46.13
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
128.04%
28.39
36.68%

Institutional Holdings

  • Slate Path Capital LP

    4.94%

  • BlackRock Inc

    4.81%

  • Vanguard Group Inc

    4.38%

  • Bleichroeder LP

    3.61%

  • Geode Capital Management, LLC

    1.67%

  • State Street Corporation

    1.41%

Corporate Announcements

  • Cue Biopharma Inc Earnings

    Cue Biopharma Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci

Organization
Cue Biopharma Inc
Employees
53
CEO
Mr. Daniel R. Passeri J.D., M.Sc.
Industry
Health Technology

Discover More

FAQs